Shanghai, China The usual cause for the fund is to invest in rounds with 1 partaker.
The fund is constantly included in less than 2 deals per year. Deals in the range of 1 - 5 millions dollars are the general things for fund. The important activity for fund was in 2018.
Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. Among the most popular fund investment industries, there are Health Care, Biotechnology. Among the various public portfolio startups of the fund, we may underline Xihua Scientific
Related Funds
| Fund Name | Location |
| 21 Invest | France, Ile-de-France, Paris |
| Ascend Technology Ventures | - |
| Cascade Seed Fund | Bend, Oregon, United States |
| Changzhou Zhongdao | Changzhou, China, Zhejiang |
| European Social Fund (ESF) | - |
| GRT Capital Partners | Boston, Massachusetts, United States |
| IDN Financials | - |
| Indian Dream Capital | - |
| Librae Holdings | - |
| LODH Immunology Fund | Geneva, Geneve, Switzerland |
| New Europe Ventures, LLC | New York, New York, United States |
| Philippine National Bank | Pasay, Pasay City, Philippines |
| Standing Oaks Venture Partners | - |
| Stanford Management | Maine, Portland, United States |
| Tiesto | - |
| Toho Bank | Fukushima, Fukushima Prefecture, Japan |
| Worldwide Innovation Challenge | - |
| Yangzhou Mandao Chuangye Touzi | China, Jiangsu, Yangzhou |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
| $120M | 22 Mar 2021 | Shanghai, China | |||
| $61M | 03 Apr 2020 | China, Shanghai | |||
| $2M | 24 Jul 2018 | Shanghai, China | |||
Wisdom | $1M | 19 Jan 2012 | Luohu District, Guangdong Province | ||
Wisdom | $463K | 03 Apr 2010 | Luohu District, Guangdong Province, China |
– EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibody development, announced today the closing of a $120m Series C financing round.
– The round was co-led by China Merchants Bank International (CMBI) and Mirae Asset Financial Group (Mirae), and joined by Hony Capital, Cormorant Asset Management, Yanchuang Capital, Octagon Capital, renowned cultural entrepreneur and investor Adrian Cheng and ShangBay Capital, with strong participation from existing investors such as Decheng Capital, SDIC Fund, Sherpa Healthcare Partners, and Hidragon Capital.
– Proceeds from the financing will be used to fund the ongoing clinical development of EMB-01, EMB-02 and EMB-06, and to expand the company’s pipeline of novel bispecific antibodies and other biologics.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
| $120M | 22 Mar 2021 | Shanghai, China | |||
| $61M | 03 Apr 2020 | China, Shanghai | |||
| $2M | 24 Jul 2018 | Shanghai, China | |||
Wisdom | $1M | 19 Jan 2012 | Luohu District, Guangdong Province | ||
Wisdom | $463K | 03 Apr 2010 | Luohu District, Guangdong Province, China |
